EA201070888A1 - Антитела и их производные - Google Patents

Антитела и их производные

Info

Publication number
EA201070888A1
EA201070888A1 EA201070888A EA201070888A EA201070888A1 EA 201070888 A1 EA201070888 A1 EA 201070888A1 EA 201070888 A EA201070888 A EA 201070888A EA 201070888 A EA201070888 A EA 201070888A EA 201070888 A1 EA201070888 A1 EA 201070888A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
derivatives
variants
chain variable
variable region
Prior art date
Application number
EA201070888A
Other languages
English (en)
Other versions
EA021284B1 (ru
Inventor
Фабио Бениньи
Даниель Д`Амбросио
Original Assignee
Лей Лайн Дженомикс С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лей Лайн Дженомикс С.П.А. filed Critical Лей Лайн Дженомикс С.П.А.
Publication of EA201070888A1 publication Critical patent/EA201070888A1/ru
Publication of EA021284B1 publication Critical patent/EA021284B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel

Abstract

Предложено антитело против TrkA, которое включает: a) вариабельную область тяжелой цепи, включающую последовательность, выбранную из BXhVH1, BXhVH2, BXhVH3, BXhVH4, BXhVH5 или HuVHWOv, приведенных на фиг. 1a; или из вариантов любой из указанных последовательностей; и/или b) вариабельную область легкой цепи, включающую последовательность, выбранную из: BXhVL1, BXhVL2, BXhVL3, BXhVL4, BXhVL5, BXhVL6, BXhVL7 или BXhVL8, приведенных на фиг. 1b, или из вариантов любой из указанных последовательностей. Также предложены производные антител, которые связывают TrkA. Антитела или производные антител согласно настоящему изобретению полезны в ряде способов лечения, включая терапию боли.
EA201070888A 2008-02-04 2009-02-04 Антитела и их производные EA021284B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2599508P 2008-02-04 2008-02-04
PCT/EP2009/051285 WO2009098238A1 (en) 2008-02-04 2009-02-04 Anti-trka antibodies and derivatives thereof

Publications (2)

Publication Number Publication Date
EA201070888A1 true EA201070888A1 (ru) 2011-04-29
EA021284B1 EA021284B1 (ru) 2015-05-29

Family

ID=40521960

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070888A EA021284B1 (ru) 2008-02-04 2009-02-04 Антитела и их производные

Country Status (21)

Country Link
US (1) US9751947B2 (ru)
EP (1) EP2252633B9 (ru)
JP (1) JP5719596B2 (ru)
KR (1) KR101782857B1 (ru)
CN (1) CN101939337B (ru)
AP (1) AP2929A (ru)
AU (1) AU2009211340B2 (ru)
BR (1) BRPI0905955A8 (ru)
CA (1) CA2713786A1 (ru)
DK (1) DK2252633T3 (ru)
EA (1) EA021284B1 (ru)
ES (1) ES2435917T3 (ru)
HK (1) HK1150314A1 (ru)
IL (1) IL207390A (ru)
MX (1) MX2010008571A (ru)
MY (1) MY191348A (ru)
NZ (1) NZ587701A (ru)
PL (1) PL2252633T3 (ru)
PT (1) PT2252633E (ru)
WO (1) WO2009098238A1 (ru)
ZA (1) ZA201006218B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
ES2435917T3 (es) 2008-02-04 2013-12-26 Lay Line Genomics S.P.A. Anticuerpos anti-Trk-A y derivados de los mismos
WO2010029497A1 (en) * 2008-09-12 2010-03-18 Pfizer Limited Treatment of endometriosis
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
KR20190112175A (ko) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US20150183885A1 (en) * 2012-06-08 2015-07-02 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
AP2014008145A0 (en) 2012-06-08 2014-12-31 Glenmark Pharmaceuticals Sa Humanized anti-trkA antibodies with animo acid substitutions
EP2674439B1 (en) 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
CN109628425A (zh) * 2019-01-02 2019-04-16 周越 一种人原肌球蛋白受体激酶a突变体及应用
CN112010978B (zh) * 2019-05-30 2022-04-08 广东东阳光药业有限公司 TrkA的抗体及其应用
WO2021092482A1 (en) * 2019-11-06 2021-05-14 The Regents Of The University Of California Compositions and methods for transferrin receptor 1 targeting
US20230357411A1 (en) * 2020-11-20 2023-11-09 Sunshine Lake Pharma Co., Ltd. Humanized anti-trka antibodies and uses thereof
CN112961244B (zh) 2021-02-28 2023-08-29 熙源安健医药（上海）有限公司 抗TrkA抗体或其抗原结合片段、其制备方法和应用
WO2023125477A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkA ANTIBODY AND APPLICATION THEREOF

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
WO1998045435A2 (en) 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB2340334B (en) * 1998-07-29 2003-06-25 Ericsson Telefon Ab L M Telephone apparatus
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
AU2003304238A1 (en) 2002-10-08 2005-01-13 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
PL211654B1 (pl) 2002-10-08 2012-06-29 Rinat Neuroscience Corp Przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego, zastosowanie tego przeciwciała do wytwarzania leku do leczenia bólu pooperacyjnego i kompozycja farmaceutyczna zawierająca przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
JP5301152B2 (ja) 2004-04-07 2013-09-25 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) * 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
ES2435917T3 (es) 2008-02-04 2013-12-26 Lay Line Genomics S.P.A. Anticuerpos anti-Trk-A y derivados de los mismos
US8460657B2 (en) 2008-06-25 2013-06-11 H. Lundbeck A/S Modulation of the TrpV: Vps10p receptor system for the treatment of pain

Also Published As

Publication number Publication date
EP2252633B1 (en) 2013-08-14
KR20100114536A (ko) 2010-10-25
ES2435917T3 (es) 2013-12-26
JP5719596B2 (ja) 2015-05-20
CN101939337B (zh) 2016-03-09
PL2252633T3 (pl) 2014-02-28
HK1150314A1 (en) 2011-11-25
MY191348A (en) 2022-06-17
NZ587701A (en) 2013-03-28
BRPI0905955A2 (pt) 2015-08-04
AU2009211340A1 (en) 2009-08-13
ES2435917T9 (es) 2014-04-02
AP2010005379A0 (en) 2010-08-31
PT2252633E (pt) 2013-11-19
CA2713786A1 (en) 2009-08-13
EA021284B1 (ru) 2015-05-29
EP2252633B9 (en) 2014-02-19
MX2010008571A (es) 2010-12-02
IL207390A0 (en) 2010-12-30
US20110145941A1 (en) 2011-06-16
KR101782857B1 (ko) 2017-09-28
BRPI0905955A8 (pt) 2018-05-08
IL207390A (en) 2015-06-30
CN101939337A (zh) 2011-01-05
WO2009098238A1 (en) 2009-08-13
DK2252633T3 (da) 2013-11-11
AU2009211340B2 (en) 2013-09-12
JP2011514314A (ja) 2011-05-06
ZA201006218B (en) 2011-08-31
US9751947B2 (en) 2017-09-05
EP2252633A1 (en) 2010-11-24
AP2929A (en) 2014-06-30

Similar Documents

Publication Publication Date Title
EA201070888A1 (ru) Антитела и их производные
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
EA201291161A2 (ru) Связывающие csf1r антитела
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA200800812A1 (ru) Композиции антитела против cd3
EA200900037A1 (ru) Моноклональные антитела против интерлейкина-6 (il-6) и их применение
CY1116886T1 (el) C-met αντισωματα
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
CO6351802A2 (es) Anticuerpos para ccr2
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
NZ594682A (en) Fully human antibodies specific to cadm1
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
NZ591056A (en) Human cytomegalovirus neutralizing antibodies and use thereof
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
NO20070985L (no) IL-17 antagonistiske antistoffer.
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
EA201492149A8 (ru) St2-антигенсвязывающие белки
ATE461220T1 (de) Anti-egfr-antikörper
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
NZ706377A (en) Il-6 antagonists and uses thereof
NZ597767A (en) Antibodies to IL-6 and use thereof
UA110358C2 (en) Molecules of antibody binding il-17a and il-17f
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür